Wegovy and Heart Issues: Making Sense of the Evidence

The cardiovascular case for Wegovy, and its limits

The SELECT trial enrolled 17,604 adults who already had cardiovascular disease and were living with overweight or obesity but did not have type 2 diabetes. Over a median of roughly 40 months, semaglutide 2.4mg reduced the combined rate of heart attack, non-fatal stroke, and cardiovascular death by 20% compared with placebo. The finding was robust enough that the MHRA granted Wegovy a second UK licence specifically for this cardiovascular indication. That is worth pausing on: this is not a theoretical benefit extrapolated from weight loss alone. The cardiovascular effect appeared earlier than the weight loss plateau, suggesting a direct action beyond simply shifting the scales.

What the evidence does not tell us is whether Wegovy is safe or appropriate for your specific cardiac history. The trial recruited people with established, stable cardiovascular disease, not everyone with a heart condition is the same. Conditions such as recent decompensated heart failure, certain arrhythmias, or a very recent cardiac event may change the prescriber's calculus considerably. If you want a fuller picture of how semaglutide interacts with heart issues, that page brings together the evidence in more detail, but it does not replace a conversation with someone who has access to your records.

The bottom line: the cardiovascular data for Wegovy is among the strongest for any weight-loss medicine currently licensed in the UK. That is genuinely good news for many people. It does not mean it is automatically appropriate for every person with heart problems.

Heart rate, rhythm, and what you should watch for

One finding that comes up regularly in practice is a modest increase in resting heart rate on semaglutide. In the SELECT trial and in STEP programme data this averaged around two to three beats per minute and was generally considered clinically unimportant in otherwise healthy cardiovascular systems. For most people it is imperceptible. If you already have a condition where heart rate matters closely (a pacemaker, certain arrhythmias, heart failure with a preserved ejection fraction) that picture is more nuanced and warrants explicit discussion with a cardiologist or your GP before you begin.

You can read more specifically about how Wegovy affects heart rate and what changes are worth reporting. On the broader question of Wegovy's relationship with cardiovascular health, the evidence is considerably more detailed than the headlines suggest. Our clinical team reviews cardiac history as part of every consultation, and if there are questions that need your GP involved, we will say so before anything is prescribed.

Symptoms that should prompt prompt medical attention include new chest pain or tightness, palpitations that feel different from your baseline, unexplained breathlessness, or fainting. These are not semaglutide-specific warnings (they are general cardiac red flags) but they are worth naming plainly here.

Existing heart medicines and how semaglutide interacts with them

Semaglutide slows gastric emptying, which can alter the absorption timing of other oral medicines. In practice, clinically significant interactions with common cardiac drugs are not well-established in the evidence base, but this is exactly the kind of nuance a prescriber checks rather than assumes. If you take anticoagulants like warfarin, certain anti-arrhythmics, or blood-pressure medicines that require consistent dosing, your prescriber will factor that in. The GI side-effect profile of semaglutide (nausea, vomiting, diarrhoea, particularly in the early weeks) can also transiently affect hydration, which matters if you are on diuretics or ACE inhibitors.

For context on the broader side-effect picture, our Wegovy overview page covers what most people experience during treatment. If liver health is a concern alongside cardiac history, this page on semaglutide and liver issues addresses the evidence there too. The key practical point: hand your prescriber a clear list of everything you take, including supplements, and do not assume any medicine is too minor to mention.

Wegovy now also carries a conditional UK authorisation for MASH (metabolic dysfunction-associated steatohepatitis, a form of fatty liver disease), which sometimes co-exists with cardiovascular risk factors, an indication worth knowing about even if it falls outside weight management.

Making a decision: what changes with a cardiac history, and what doesn't

If you are sitting with a cardiac diagnosis, looking at this page, wondering whether Wegovy is still on the table for you, that is a very common position to be in, and it is not an easy one. The honest answer is: it may well be, but the process needs to be more thorough, not less.

The private route through a regulated online pharmacy is only appropriate where a prescriber can see your full clinical picture. At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber on the same day, a real clinician, reading your answers, not a form that ticks boxes. Where a GP conversation is needed first, we say so clearly. We also notify your GP in line with GPhC guidance. There is no pressure, and there are no shortcuts where safety is concerned.

If after this you want to look at cost alongside clinical suitability, this page on accessing Wegovy privately sets out what is involved. And if your questions run broader than cardiac issues, our FAQs cover the most common practical points. When you feel ready, you can speak to our prescribers through a free consultation and get a clear answer specific to you.